SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1  by Cuenda, Ana et al.
FEBS 15429 FEBS Letters 364 (19951 229 233 
SB 203580 is a specific inhibitor of a MAP kinase homologue 
which is stimulated by cellular stresses and interleukin-1 
Ana Cuenda ~'**, John Rouse a'**, Yair N. Doza", Roger Meier a, Philip Cohen "'*, 
Timothy F. Gallagher b,Peter R. Young b, John C. Lee b 
~MRC Protein Phosphorylation Unit, Department of Biochemistry, University o[ Dundee, Dundee DDI 4HN. Scotland. UK 
bSmithKline Beecham Pharmaceuticals, K#tg ~['Prussia. PA 19406, USA 
Received 19 February 1995: revised version received 20 March 1995 
Abstract A class of pyridinyl imidazoles inhibit the MAP kinase 
homologue, termed here reactivating kinase (RK) [Lee et al. 
(1994) Nature 372, 739-746]. We now show that one of these 
compounds (SB 203580) inhibits RK in vitro (ICs0 = 0.6 pM), 
suppresses the activation of MAPKAP kinase-2 and prevents the 
phosphorylation of heat shock protein (HSP) 27 in response to 
interleukin-1, cellular stresses and bacterial endotoxin in vivo. 
These results establish that MAPKAP kinase-2 is a physiological 
RK substrate, and that HSP27 is phosphorylated by MAPKAP 
kinase-2 in vivo. The specificity of SB 203580 was indicated by 
its failure to inhibit 12 other protein kinases in vitro, and by its 
lack of effect on the activation of RK kinase and other MAP 
kinase cascades in vivo. We suggest hat SB 203580 will be useful 
for identifying other physiological roles and targets of RK and 
MAPKAP kinase-2. 
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I. Introduction 
We have previously identified and characterised a protein 
kinase which is active only after phosphorylation by the p42 or 
p44 isoforms of mitogen-activated protein (MAP) kinase [1,2] 
and termed it MAP kinase-activated protein (MAPKAP) ki- 
nase-2 to distinguish it from the RSK family of ribosomal 
protein $6 kinases (MAPKAP kinases-1) which are also acti- 
vated by MAP kinase. However, we recently made the surpris- 
ing finding that MAPKAP kinase-2 is not activated in vivo by 
growth factors which are potent activators of p42/p44 MAP 
kinases, but instead by chemical or osmotic stress and heat 
shock [3]. These cellular stresses timulate a distinct MAP ki- 
nase homologue, termed the 'reactivating kinase' (RK), which 
also activates MAPKAP kinase-2 in vitro [3]. Other laborato- 
ries also identified the RK in a B-cell line transfected with the 
bacterial endotoxin (LPS) receptor and in routine macrophages 
where it is activated in response to LPS (termed p38 in [4]), and 
in KB cells where it is activated by interleukin-I (IL-1) (termed 
p40 in [5]). 
The amino acid sequence of the RK [3,4] is most similar to 
HOG- l ,  a MAP kinase homologue which lies in a signalling 
pathway that restores the osmotic gradient across the cell mem- 
brane ofS. cerevisiae in response to increased external osmolar- 
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ity [6]. These enzymes are distinguished by the sequence TGY 
in the activation domain, which differs from the TEY sequence 
found in p42 and p44 MAP kinases and the TPY sequence 
found in the MAP kinase homologue JNK  JNK is activated 
in vivo by similar stimuli to those which activate the RK, 
including heat shock [8], osmotic stress [9] and I L- I [10] and one 
of its cellular roles is to activate the transcription factor c-Jun 
[7,8]. A MAP kinase kinase homologue capable of activating 
both the RK and JNK in vitro has recently been identified 
[11,12] This enzyme is most similar to PBS2, which lies above 
HOG-1 in the yeast osmoregulation pathway. 
Two homologues of the RK, termed CSAID binding pro- 
teins 1 and 2 (CSBP1, CSBP2), have recently been identified in 
human monocytes as proteins that interact specifically with, 
and are inhibited by, CSAIDs, a novel class of pyridinyl imi- 
dazoles ([13]; Fig. 1). These drugs inhibit the LPS-induced syn- 
thesis of inflammatory cytokines (IL-1 and tumour necrosis 
factor (TNF)) at the translational level [13,14] and may be 
useful in the treatment of inflammatory diseases, such as rheu- 
matoid arthritis. CSBP2 is the human homologue of murine 
RK [4,13], while the nucleotide and amino acid sequence of 
CSBP1 is identical, except for 75 nucleotides corresponding to
amino acid residues 230-254. Here we report that the pyridinyl 
imidazole SB 203580 is a specific inhibitor of the RK in vitro, 
which prevents the activation of MAPKAP kinase-2 and the 
phosphorylation of HSP27 in vivo by cellular stresses, IL-I 
and LPS. These results suggest hat SB 203580 is a powerful 
new tool to identify physiological roles of the RK signalling 
pathway. 
2. Materials and methods 
2.1. Materials 
1L-I was purchased from Boehringer, and HSP27 protein and anti- 
HSP27 antibodies from Stressgen. Anti-MAPKAP kinase-2 antibodies 
were raised in sheep against a mixture of three peptides HVKSGLQI- 
KKNA, KEDKERWEDVKEEMTS and STKVPQTPLHTSR corre- 
sponding to sequences found in human MAPKAP kinase-2 [2] and 
affinity purified on a peptide-Affigel 15 column. CSBP-2 was expressed 
in E. coli as a His-tagged fusion protein, purified on nickel nitrilotriace- 
tate-agarose [13] and activated with the RK kinase (RKKI from arsen- 
ite-stimulated PC12 cells [3]. p42 MAP kinase [1] and the first 194 
residues of c-Jun were expressed in E. coil as GST fusion proteins and 
purified on glutathione-Sepharose. Beads containing 0.35 mg GST- 
cJun per ml of glutathione-Sepharose were stored at -20°C. Pyridinyl- 
imidazoles were synthesized at SmithKline Beecham (T. Gallagher el 
al., in preparation) and dissolved in sterile dimethylsulphoxide (Sigma) 
to give 20 mM solutions. 
2.2. Partial pur(fication and assay of stress-activated protein kinases 
PC12 [15], HeLa [3], THP-I[13] and KB cells [5] were cultured, 
exposed to cellular stresses or cytokines, lysed in the presence of protein 
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Fig. 1. The structures of SB 203580 and SK&F 105809. 
phosphatase inhibitors and chromatographed on Mono Q as in [3]. The 
major peak of c-Jun kinase (JNK) etuted at 60 70 mM NaCI in frac- 
tions 4/5 (data not shown), the RKK at 170 180 mM NaCI in fractions 
8 10 and the RK at 0.35 M NaC1 in fractions 19/20 [3]. MAPKAP 
kinase-2 is not retained by Mono Q and was partially purified by 
chromatographing theflowthrough fractions on Mono S [3]. 
The RK and activated CSBP2 were assayed by the activation of 
MAPKAP kinase-2 [3] and its drug binding activity by photoaffinity 
labelling with radiolabelled SB 206718 [13]. MAPKAP kinase-2 was 
assayed using the synthetic peptide substrate KKLNRTLSVA [2] and 
JNK with GST-cJun [16]. c-Raf, MAPKK and p42 m~'pk were assayed 
as in [17], p90 and p70 $6 kinases as in [18]. Protein kinase A and casein 
kinase-2 were assayed using the synthetic peptides LRRASVA and 
RRREEESEEE as described for MAPKAP kinase-2 and phosphory- 
lase kinase as in [19]. Cyclin-dependent protein kinases were assayed 
with histone H1 [20] and protein phosphatases t and 2A as in [21]. 
2.3 HSP27 phosphoo,lation i KB and PCI2 cells 
Confluent cells grown on 6 cm diameter dishes were washed four 
times with phosphate-free DMEM containing 10% dialysed foetal calf 
serum, then incubated for 3 h in the same medium supplemented with 
0.5 mCi (KB) or 0.3 mCi (PC I2) of 32P-labelled orthophosphate before 
exposure to cellular stresses, growth factors or cytokines. After stimu- 
lation, each dish of cells was washed three times with ice-cold 20 mM 
sodium phosphate, pH 7.4, 0.15 M NaCI and lysed in 0.4 ml of 20 mM 
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Fig. 3. Effect of pyridinyl imidazoles on RK activity in vitro. (A) Effect 
of SB 203580 (circles) and SK&F 105809 (triangles) on RK activity 
from chemically stressed (0.5 mM sodium arsenite) PC12 cells (closed 
symbols) and on bacterially expressed human CSBP-2 (open symbols) 
which had been activated with RKK from arsenite-stimulated PCI2 
cells. (B) Effect of SB 203580 on the RK from heat-shocked (10 min, 
45°C) HeLa cells (closed circles) and osmotically shocked (5 min with 
0.5 M sorbitol) PCI2 cells (open circles), and on bacterially expressed 
p42 MAP kinase activated in vitro by MAP kinase kinase (closed 
triangles) and JNK from arsenite-stimulated PCI2 cells (open trian- 
gles). 
Tris acetate, pH 7.0 (20°C), 0.27 M sucrose, 1 mM EDTA, I mM 
EGTA, 1 mM sodium orthovanadate, 1% (by mass) Triton X-100, 10 
mM sodium fl-glycerophosphate, 25 mM sodium fluoride, 2.5 mM 
sodium pyrophosphate, 0.1% (by vol.) 2-mercaptoethanol, 1 mM ben- 
zamidine and 4 ¢tg/ml eupeptin. After centrifugation for 5 min at 
13,000 x g, the supernatant from PCI2 cells (10~1) was electrophoresed 
on 10% polyacrylamide g ls and autoradiographed to locate HSP27. 
For KB cells, 0.05 ml aliquots were incubated for 2 h at 4°C with 0.01 
ml of 50% (by mass) Protein G-Sepharose (Pharmacia) conjugated to 
10/~g of anti-HSP27 antibody. The suspension was centrifuged for 
1 min at 13,000 x g, the supernatant discarded and the antibody/Pro- 
tein G-Sepharose pellet washed three times with lysis buffer containing 
0.5 M NaC1 and twice in lysis buffer. After denaturation i  1% SDS 
and heating for 5 min at 100°C, the samples were electrophoresed on 
15% polyacrylamide g ls and autoradiographed to localise HSP27. 
3. Results 
3.1. SB  203580 is a ,spec!fic inhibitor o f  the RK  in vitro 
The structures of two pyridinyl imidazoles employed in this 
study are shown in Fig. 1. SB 203580 is a potent inhibitor of 
LPS-induced cytokine synthesis in the human monocyte cell 
line THP-1 (ICs0 = 50-100 nM), while the analogue SK&F 
105809 does not inhibit cytokine synthesis. 
The RK was partially purified from arsenite-stimulated PC12 
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Fig. 2. SB 206718, a r diolabelled photoaffinity analogue of SB 203580, binds covalently to the RK. Lysates from arsenite-stimulated PC12 cells 
(A) or heat-shocked (10 min, 45°C) HeLa cells (B) were chromatographed on Mono Q and, as described previously, RK activity was detected only 
in fractions 19 and 20 [3]. Aliquots of the 40 fractions from each column (0.5 ml) were incubated with SB 206718, electrophoresed on SDS/ 
polyacrylamide g ls and autoradiographed [13]. A single radiolabelled band co-migrating with the RK (42 kDa) was detected in fractions 19 and 
20, and binding was specific because an excess of unlabelled ligand (+) abrogated the radiolabelled band. 
A. Cuenda et al./FEBS Letters 364 (1995) 229 233 231 
Fig. 4. SB 203580 inhibits the in vivo activation of MAPKAP kinase-2 
by a variety of stimuli. (A) PCI2 cells were incubated for 15 min in the 
absence (open symbols) or presence (closed symbols) of 25 ~M SB 
203580 and then for 15 rain with 0.5 mM sodium arsenite in the contin- 
ued presence of SB 203580. The cells were lysed, and the lysates (8 mg 
protein) chromatographed on 5 x 0.5 cm column of Mono S as in [3]. 
The flow rate was 1 ml/min and fractions of 1.0 ml were collected and 
assayed for MAPKAP kinase-2 activity using the peptide 
KKLNRTLSVA. The NaC1 gradient is shown by the broken line. 
(B) THP-I cells were incubated for 60 rain in the absence (open circles) 
or presence (closed circles) of 10/aM SB 203580 and then for 15 rain 
with 100 ng/ml LPS in the continued presence of the inhibitor. The cells 
were lysed and 0.3 mg chromatographed on a 5 x 0.16 cm column of 
Mono S using a Pharmacia Smart System. The flow rate was 0.1 ml and 
fractions of 0.1 ml were collected and assayed for MAPKAP kinase-2 
as in (A). The open triangles show an experiment in which both SB 
203580 and LPS were omitted. (C) KB cells were stimulated for 15 min 
with 0.5 mM sodium arsenite or 20 ng/ml IL-I or 0.5 M sorbitol. After 
lysis, 0.3 mg protein was chromatographed on Mono S as in (B), and 
the activity associated with major peak of MAPKAP kinase-2 was 
quantitated (filled bars). The hatched bars show experiments in which 
cells were incubated for 1 h with 10/IM SB 203580 prior to stimulation 
and the open bars the results from unstimulated cells not preincubated 
with SB 203580. The results are shown _+S.E.M. for 3 experiments. 
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cells and heat-shocked HeLa cells by chromatography on 
Mono Q, eluting in fractions 19 and 20 at 0.35 M NaC1 as 
described previously [3]. The fractions from each column were 
incubated with a radiolabelled photoaffinity ligand SB 206718, 
an analogue of SB 203580 [13]. Upon photoactivation, a single 
competable radiolabelled band of the expected molecular mass 
(42 kDa) was detected in fractions 19 and 20 from both columns 
(Fig. 2A,B), and in none of the other 40 fractions, further 
establishing the identity of RK and CSBP. 
SB 203580 inhibited the RK from heat-shocked HeLa cells 
(Fig. 3A), osmotically stressed PC12 cells (Fig. 3B) or bacteri- 
ally expressed CSBP-2 (Fig. 3A) with an ICs0 of 0.6 /,tM. 
SB 203580 (0.1 mM) did not inhibit 12 other protein kinases 
tested in vitro, including the MAP kinase homologues JNK and 
p42 MAP kinase (Fig. 3B, Table 1), nor did it inhibit two 
protein serine/threonine phosphatases (Table 1). SK&F 
105809, an analogue of SB 203580 (Fig. l), which does not 
inhibit LPS-induced IL-1 and TNF  synthesis in monocytes, did 
not inhibit the RK in vitro (Fig. 3A). 
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3.2. SB 203580 prevents the activation qf MAPKAP kinase-2 
ill vivo 
Preincubation with SB 203580 prevented the activation of 
MAPKAP kinase-2 by arsenite in PCI2 cells (Fig. 4A) and by 
LPS in THP-1 cells (Fig. 4B). The same concentration of SB 
203580 (25/tM) did not inhibit the activation of the RK kinase 
(the upstream activator of RK) by arsenite in PCI2 cells or by 
IL-I in KB cells. SB 203580 (25 pM) also did not inhibit the 
activation of JNK  by arsenite in PCI2 cells or by IL-I in KB 
cells, or the activation of p42 MAP kinase by NGF in PCI2 
cells or EGF  in KB cells (data not shown). 
SB203580 strongly suppressed the activation of MAPKAP 
kinase-2 by ]L-l ,  osmotic stress or arsenite in KB cells (Fig. 
4C). The MAPKAP kinase-2 activity induced by all three stim- 
uli eluted from Mono S as one major peak at the same NaCI 
concentration as MAPKAP kinase-2 from PCI2 or THPI  cells 
and could be immunoprecipitated quantitatively by anti- 
MAPKAP kinase-2 antibodies (data not shown). 
3.3. SB 203580 prevents the phosphorylation qf heat shock 
protein 27 hy cellular stresses or IL-1 
MAPKAP kinase-2 phosphorylates the small heat shock 
proteins (hereafter termed HSP27) in vitro at the same serine 
residues [22] which are phosphorylated in vivo in response to 
heat shock, IL-1 and other stimuli which activate MAPKAP 
kinase-2 [5,23,24]. Moreover, HSP27 kinase activity co-purifies 
with MAPKAP kinase-2 from skeletal muscle [22] and the 
major HSP27 kinase activity induced by IL-1 in KB cells co- 
elutes with MAPKAP kinase-2 on Mono S and is immunopre- 
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cipitated quantitatively and specifically by HSP27 antibodies 
(data not shown). 
The in vivo phosphorylation state of HSP27 was low in 
unstimulated KB cells, but increased strikingly after stimula- 
tion with IL-1 or exposure to chemical or osmotic stress (Fig. 
5A). Prior incubation of cells with SB 203580 suppressed the 
phosphorylation f HSP27 by every stimulus with an ICs, , value 
of < l/ JM (Fig. 5A). The phosphorylation f HSP27 induced 
by arsenite in PC I2 cells was also prevented by SB 203580 (Fig. 
5B). The effect of SB 203580 on the phosphorylation f HSP27 
was highly specific because this drug had no effect on the 
phosphorylation state of any of the major 32p-labelled proteins 
in PC12 and KB cells that were resolved by one-dimensional 
SDS/polyacrylamide g lelectrophoresis (data not shown). 
3.4. Phosphorylation o f  l iSP27  in PCI2 cells is not induced 
by NGF 
The results presented in section 3.2 and [3] indicated that 
MAPKAP kinase-2 was activated by the RK in vivo, and not 
by p42/p44 MAP kinase. In this case, an agonist like NGF in 
PC12 cells, which strongly activates p42/p44 MAP kinases but 
does not activate MAPKAP kinase-2, should not stimulate the 
phosphorylation f HSP27. The results hown in Fig. 5C show 
that this is indeed the case. In contrast, the expected increase 
in HSP27 phosphorylation ccurred in response to arsenite in 
a parallel experiment (Fig. 5B). 
4. Discussion 
In this paper we show that SB 203580 is a remarkably specific 
inhibitor of the RK in vitro (Table 1, Fig. 3) and that it does 
not prevent he activation of RK kinase or other MAP kinase 
pathways in vivo. We have therefore xploited the specificity 
of this compound to establish that MAPKAP kinase-2 is a 
physiological substrate of the RK (Fig. 4) and that HSP27 is 
a physiological target for MAPKAP kinase-2 (Fig. 5). Thus the 
stimuli which activated MAPKAP kinase-2 also promoted the 
phosphorylation f HSP27, and SB 203580, which prevented 
the activation of MAPKAP kinase-2 by each agonist, also 
blocked the phosphorylation f HSP27 in vivo (Fig. 5). NGF, 
a potent activator of p42 and p44 MAP kinases in PC12 cells 
[15], does not activate MAPKAP kinase-2 [3] and did not stim- 
ulate HSP27 phosphorylation (Fig. 5C). This finding, in con- 
junction with the suppression ofHSP27 phosphorylation bySB 
203580, demonstrates that p42 and p44 MAP kinases are not 
required for the activation of MAPKAP kinase-2 or the phos- 
phorylation of HSP27 in the cells we have studied so far. The 
role of HSP27 phosphorylation is ot yet established, but recent 
evidence suggests that it may promote actin polymerisation a d 
so counteract the disruptive ffects of stress on actin microfil- 
ament structure, thereby aiding cell survival [25]. 
SB 203580 was originally discovered as an inhibitor of LPS- 
induced cytokine synthesis in THP-1 monocytes [13]. The ob- 
servations that LPS activates MAPKAP kinase-2 in these cells 
and that this is prevented by SB 203580 (Fig. 4B) is therefore 
of particular interest, since it implies that the protein phospho- 
rylation event(s) which triggers cytokine synthesis may be 
catalysed by either the RK or by MAPKAP kinase-2. The 
concentration f SB203580 which inhibits LPS-induced cytok- 
ine synthesis by 50% in THP-1 cells (50 100 riM) is somewhat 
lower than that found to inhibit activation of MAPKAP ki- 
nase-2 in vitro in the present study. The most likely explanation 
for this apparent discrepancy is that prolonged incubation with 
SB 203580 leads to its accumulation i cells. The assays for 
inhibition of cytokine synthesis in monocytes involve an 18 h 
incubation with SB 203580 [13], and indeed we have found that 
if THP-I cells are incubated for 18 h with SB 203580 prior to 
stimulation with LPS (instead of the brief 15-60 min incuba- 
tions employed throughout this study), the ICs0 for inhibition 
of MAPKAP kinase-2 activation is reduced to about 100 nM 
t,\. Cuenda, unpublished observations). 
IL-I was shown previously to activate a protein kinase cas- 
cade in KB cells in which an HSP27 kinase (termed p50) is 
activated by another protein kinase (p40) [5]. The sequences of
several peptides from p40 identified it as the RK, but the rela- 
tionship of I L-l-activated p50 to the stress-activated MAPKAP 
kinase-2 was uncertain. Here we have established that p50 is 
either MAPKAP kinase-2 or a very closely related isoform. 
IL-1 and cellular stresses both induced a MAPKAP kinase-2 
activity in KB cells (Fig. 4C) which coeluted uring Mono S 
chromatography with HSP27 kinase and which was im- 
munoprecipitated with anti-MAPKAP kinase-2 antibodies 
(data not shown). Moreover, the anti-MAPKAP kinase-2 anti- 
bodies recognised a single 50 kDa species in human KB cell 
extracts which coeluted with MAPKAP kinase-2 on Mono S 
(data not shown). Finally, the activation of MAPKAP kinase-2 
in this cell line by either IL-1 or cellular stresses was suppressed 
by SB 203580 (Fig. 4C). 
The vast array of protein kinases in mammalian cells, which 
are all members of the same superfamily, has led many to doubt 
whether compounds that are really specific inhibitors of a single 
protein kinase can be synthesized. However, the recent identifi- 
cation of rapamycin as a specific inhibitor of the activation of 
p70 $6 kinase [26], the synthesis of a potent and specific inhib- 
itor of the EGF receptor kinase [27] and the present finding that 
Table 1 
Effect of SB 203580 
phosphatases 
on the activities of protein kinases and 
Protein kinase SB 203580 Activity 
Concn. (#M) (% control) 
RK/p38 1 35 +- 1 
RK/p38 10 5 -+ 1 
MAPKAP kinase-2 100 92 _+ 3 
JNK/SAP kinase 100 86 + 4 
p42 MAP kinase 100 97 + 3 
MAP kinase kinase 100 93 _+ 4 
c-Raf 100 87 + 2 
p90 $6 kinase 100 103 + 2 
p70 $6 kinase 100 97 + 4 
protein kinase A 100 99 + 2 
phosphorylase kinase 100 97 + 1 
cyclin A/cdk2 100 91 _+ 4 
cyclin E/cdk2 100 112 _+ 6 
casein kinase-2 100 99 + 2 
protein phosphatase-I 100 97 + 4 
protein phosphatase 2A 100 106 + 6 
Activities are given + S.E.M. for three separate determinations relative 
to control incubations inwhich the inhibitor was omitted. We thank 
colleagues in the MRC Protein Phosphorylation Unit (Dario Alessi, 
Craig Jones, lan Leighton and Robert MacKintosh for carrying out the 
assays of c-Raf, cyclin-dependent protein kinases, p70 $6 kinase and 
protein phosphatases, respectively, and Ted Hupp (Biochemistry De- 
partment, University of Dundee) for supplying casein kinase-2. 
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Fig. 5. SB 203580 blocks the phosphorylation f HSP27 induced by 
several agonists in KB and PC 12 cells. Cells were incubated with [32P]or- 
thophosphate, and tbr 1 h with the indicated concentrations of SB 
203580 and stimulated as described below. (A) KB cells were stimulated 
for 20 min with 0.5 mM sodium arsenite or 20 ng/ml IL-I, or for 15 min 
with 0.5 M sorbitol. The cells were washed and lysed, and HSP27 
immunoprecipitated, then denatured in SDS and electrophoresed on
15% polyacrylamide g ls. The figure shows autoradiographs of the gels. 
The lanes marked C (control) show the labelling of HSP27 in unstimu- 
lated cells where SB 203580 was omitted. The different intensities of the 
lanes marked C is not due to a variable basal evel of HSP27 phospho- 
rylation in different experiments, but to different lengths of autoradi- 
ography. (B) PCI2 cells were incubated for 30 min in the absence or 
presence of 10 ,uM SB 203580 (I, inhibitor) and then stimulated for 15 
rain with arsenite in the continued presence of the inhibitor (A). SB 
203580 and arsenite were omitted in a control (C) experiment. After 
lysis, aliquots were electrophoresed on 10% polyacrylamide gels and 
autoradiographed. (C) Same as B except hat PC12 cells were stimu- 
lated for 15 rain with 50 ng/ml NGF (N) or 0.5 mM sodium arsenite 
(A) or buffer (C, control). 
SB 203580 is a specific inhibitor of the RK, has demonstrated 
that highly specific inhibitors can indeed be developed. We 
suggest that SB 203580 will be useful for identifying novel 
physiological roles and substrates of the RK and MAPKAP 
kinase-2. 
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